Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ARCHIVE
ARCHIVE
- Fee-for-Service Reimbursement to Be Permitted for Wider Range of High-priced Drugs
August 15, 2011
- SRUVEY
August 15, 2011
- Female Life Expectancy Down Slightly in 2010; First Decline in 5 Years
August 15, 2011
- PMDA to Initiate Clinical Trial Consultation for Orphan Drugs
August 15, 2011
- Takeda Discontinues Development of Anti-obesity Drug in US
August 15, 2011
- Growth in Diabetes Drug Market Driven by DPP-4 Inhibitors in 2010: Yano Research
August 15, 2011
- JPA President Kodama to Explain about Leaked Copy of His Appeal at General Assembly
August 15, 2011
- NCCHD Creates Pediatric Clinical Trial Network of 27 Facilities
August 15, 2011
- MSD Invites Former JPMA Director General as Compliance Adviser
August 15, 2011
- Kowa Obtains Marketing Approval for Pitavastatin in Mexico
August 15, 2011
- Gov't Council Submits 4th Science & Technology Basic Plan
August 15, 2011
- Kyowa Kirin Aims for 70% Increase in Sales for UK Subsidiary ProStrakan by 2013
August 15, 2011
- AZ's New Antiplatelet Agent Ticagrelor Approved by the FDA
August 15, 2011
- Shionogi Completes New Core Research Facility in Toyonaka
August 15, 2011
- Top-100 Product Ranking Affected by Premium, Price Revisions
August 15, 2011
- RoACTEMRA Approved for sJIA in Children 2 Years or Older in Europe
August 15, 2011
- Tella Announces Research Results for Dendritic Cell Vaccine Therapy
August 15, 2011
- Aricept Has Overwhelming Advantage in AD Market in Japan: Mr Honda
August 15, 2011
- Roche's Tarceva Receives Positive Opinion from CHMP for 1st-Line NSCLC Therapy
August 15, 2011
- Korosho Starts Inviting Requests for Approval of Unapproved Drugs/Indications
August 15, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…